Drugs / XS-04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06820268 | Jan 2025 → Nov 2027 expected | B-cell neoplasm, acute myeloid leukemia, myelodysplastic syndrome | NovaOnco Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XS-04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06820268 ↗ |
| Route | Oral | “Each treatment cycle is 28 days, with continuous oral administration, twice daily.” NCT06820268 ↗ |